Chapter title |
Introduction to RNA Vaccines.
|
---|---|
Chapter number | 1 |
Book title |
RNA Vaccines
|
Published in |
Methods in molecular biology, January 2017
|
DOI | 10.1007/978-1-4939-6481-9_1 |
Pubmed ID | |
Book ISBNs |
978-1-4939-6479-6, 978-1-4939-6481-9
|
Authors |
Thomas Kramps, Knut Elbers, Kramps, Thomas, Elbers, Knut |
Editors |
Thomas Kramps, Knut Elbers |
Abstract |
RNA vaccines are attractive, because they exhibit characteristics of subunit vaccines and live-attenuated vectors, including flexible production and induction of both humoral and cellular immunity. While human proof-of-concept for RNA vaccines is still pending, the nascent field of RNA therapeutics has already attracted substantial industry and government funding as well as record investments of private venture capital. Most recently, the WHO acknowledged messenger RNA (mRNA) as a new therapeutic class. In this chapter, we briefly review key developments in RNA vaccines and outline the contents of this volume of Methods in Molecular Biology. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 1 | 14% |
Unknown | 6 | 86% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 7 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 168 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 29 | 17% |
Student > Master | 24 | 14% |
Student > Bachelor | 23 | 14% |
Student > Ph. D. Student | 19 | 11% |
Professor | 7 | 4% |
Other | 20 | 12% |
Unknown | 46 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 42 | 25% |
Agricultural and Biological Sciences | 16 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 15 | 9% |
Medicine and Dentistry | 10 | 6% |
Immunology and Microbiology | 9 | 5% |
Other | 25 | 15% |
Unknown | 51 | 30% |